ABSTRACT
Youth is the core force of social and economic development, once the occurrence of youth stroke will place a heavy burden on society and family. However, the prevention and control of stroke in China is mainly aimed at middle-aged and elderly patients, the part of young stroke is relatively easy to be ignored. This article focuses on the characteristics, research progress, prevention and control status of young stroke, pointing out the importance of centering on the prevention and treatment of young stroke. At the same time, it hopes that the industry can concentrate on the prevention and treatment of young stroke, making precise policies in the future, and developing secondary prevention guidelines for the causes or risk factors of young stroke, so as to improve comprehensive stroke prevention and control system. On this basis, the health level of the whole population will be improved, and the life expectancy of residents will be extended, thus promoting the realization of the strategic goal of "Healthy China 2030".
Subject(s)
Adolescent , Aged , Humans , Middle Aged , China/epidemiology , Health Status , Life Expectancy , Policy , Stroke/prevention & controlABSTRACT
AIM@#To investigate the active constituents of Lignum Sappan (Caesalpinia sappan L.) on growth-related signaling and cell mitosis.@*METHOD@#The influence of the ethyl acetate (EtOAc) extract of Lignum Sappan and its constituents on growth-related signaling were evaluated by a luciferase assay in cells stably-transfected with NF-κB, STAT1, or STAT3 responsive luciferase reporter plasmid. The inhibitory effect on the cell cycle was determined by flow cytometric analysis. The anti-tumor activities were assessed in vitro and in vivo.@*RESULTS@#The EtOAc extract of Lignum Sappan had inhibitory activities on growth-related signaling and cell mitosis. Three major active compounds were sappanchalcone, brazilin, and butein. Sappanchalcone blocked cell cycle progression in the G2/M phase, brazilin inhibited TNFα/NF-κB signaling, while butein inhibited IL-6/STAT3 signaling, as well as TNFα/NF-κB signaling. The three compounds all demonstrated cytotoxic activities against human tumor cells in vitro. In a S180 tumor cell-bearing mice model, the anti-tumor efficacy of the EtOAc extract was better than the individual compounds acting alone.@*CONCLUSION@#These results indicate that Lignum Sappan contains multiple active compounds with different antitumor activities, which act synergistically to enhance their anti-tumor effects. The EtOAc extract of Lignum Sappan may be better than individual active constituent as a novel medicine for the treatment of cancer.
Subject(s)
Animals , Humans , Male , Antineoplastic Agents, Phytogenic , Pharmacology , Therapeutic Uses , Benzopyrans , Pharmacology , Therapeutic Uses , Caesalpinia , Cell Cycle Checkpoints , Chalcones , Pharmacology , Therapeutic Uses , Hep G2 Cells , Interleukin-6 , Metabolism , Mice, Inbred BALB C , Mitosis , NF-kappa B , Metabolism , Phytotherapy , Plant Extracts , Pharmacology , Therapeutic Uses , STAT3 Transcription Factor , Metabolism , Sarcoma , Drug Therapy , Metabolism , Signal Transduction , Tumor Necrosis Factor-alpha , MetabolismABSTRACT
<p><b>OBJECTIVE</b>To evaluate the clinical efficacy of modified Daotan Decoction (DD) combining low dosage of risperidone in treating chronic schizophrenia patients of phlegm-dampness blockage type, and compare with patients treated with risperidone alone.</p><p><b>METHODS</b>Sixty-five inpatients were randomly assigned to two groups, the treatment group (34 cases) treated with DD (with conventional dosage) one dose per day and risperidone 3.16 +/- 0.73 mg/d, and the control group (31 cases) treated with risperidone 5.11 +/- 1.27 mg/d alone, the course for both groups was 8 weeks. The effect was evaluated with positive and negative syndrome scale (PANSS), and the adverse reaction was assessed with treatment emergent symptom scale (TESS).</p><p><b>RESULTS</b>There was no significant difference in the overall efficacy between the two groups, but the improvement of the negative symptoms, illness provocation and general psychopathologic condition was significantly better in the treatment group than that in the control group respectively (P < 0.05). Moreover, the adverse reaction was milder and less in the former than that in the latter.</p><p><b>CONCLUSION</b>The treatment of DD combined with low dosage of risperidone is effective on chronic schizophrenia and shows less adverse reaction.</p>